Literature DB >> 678387

Pharmacokinetic and pharmacodynamic studies with long-acting propranolol.

J McAinsh, N S Baber, R Smith, J Young.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 678387      PMCID： PMC1429409          DOI： 10.1111/j.1365-2125.1978.tb00835.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  8 in total

1.  Studies of the absorption and removal of propranolol in hypertensive patients during therapy.

Authors:  C A Chidsey; P Morselli; G Bianchetti; A Morganti; G Leonetti; A Zanchetti
Journal:  Circulation       Date:  1975-08       Impact factor: 29.690

Review 2.  Individualization of propranolol therapy.

Authors:  D G Shand
Journal:  Med Clin North Am       Date:  1974-09       Impact factor: 5.456

3.  The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat.

Authors:  G H Evans; A S Nies; D G Shand
Journal:  J Pharmacol Exp Ther       Date:  1973-07       Impact factor: 4.030

4.  Propranolol in hypertension: a study of long-term therapy, 1964-1970.

Authors:  F J Zacharias; K J Cowen; J Prestt; J Vickers; B G Wall
Journal:  Am Heart J       Date:  1972-06       Impact factor: 4.749

5.  To be taken as directed.

Authors:  M S Gatley
Journal:  J R Coll Gen Pract       Date:  1968-07

6.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

7.  Propranolol given twice daily in hypertension.

Authors:  G Berglund; O Andersson; L Hansson; R Olander
Journal:  Acta Med Scand       Date:  1973-12

8.  beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335
  8 in total
  39 in total

Review 1.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

Review 2.  Clinical significance of pharmacokinetic models of hepatic elimination.

Authors:  D J Morgan; R A Smallwood
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

3.  A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls.

Authors:  R G Watson; W Bastain; K A Larkin; J R Hayes; J A McAinsh; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

4.  Plasma levels and negative chronotropic effect of metoprolol following single doses of a conventional and sustained-release formulation.

Authors:  C P Quaterman; M J Kendall; P G Welling
Journal:  Eur J Clin Pharmacol       Date:  1979-03-26       Impact factor: 2.953

5.  Once daily administration of sustained release propranolol capsules in the treatment of angina pectoris.

Authors:  H Halkin; I Vered; A Saginer; B Rabinowitz
Journal:  Eur J Clin Pharmacol       Date:  1979       Impact factor: 2.953

6.  Beta-adrenoceptor blockers and the blood-brian barrier.

Authors:  G Neil-Dwyer; J Bartlett; J McAinsh; J M Cruickshank
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

7.  Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug.

Authors:  K Balnave; J D Neill; C J Russell; D W Harron; W J Leahey; R Wilson; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

8.  Comparison of the efficacy and acceptability of nicardipine and propranolol, alone and in combination, in mild to moderate hypertension.

Authors:  D Maclean; E T Mitchell; E M Laing; F C Macdonald; K J Gough; R J Dow; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

9.  Comparative pharmacological and pharmacokinetic observations on propranolol (long acting formulation) and bendrofluazide administered separately and concurrently to volunteers.

Authors:  D P Nicholls; D W Harron; J McAinsh; W M Castle; N P Barker; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

Review 10.  Pharmacokinetics of long acting propranolol. Implications for therapeutic use.

Authors:  G S Nace; A J Wood
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.